Gross Profit Analysis: Comparing United Therapeutics Corporation and Perrigo Company plc

Pharma Giants' Profit Battle: United Therapeutics vs. Perrigo

__timestampPerrigo Company plcUnited Therapeutics Corporation
Wednesday, January 1, 201414477000001162636000
Thursday, January 1, 201517124000001396725000
Friday, January 1, 201620518000001526100000
Sunday, January 1, 201719795000001619600000
Monday, January 1, 201818315000001429100000
Tuesday, January 1, 201917733000001331200000
Wednesday, January 1, 202018152000001375200000
Friday, January 1, 202114162000001563000000
Saturday, January 1, 202214554000001789600000
Sunday, January 1, 202316804000002070000000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: United Therapeutics vs. Perrigo

In the competitive landscape of the pharmaceutical industry, understanding financial performance is crucial. This analysis compares the gross profit trends of United Therapeutics Corporation and Perrigo Company plc from 2014 to 2023. Over this period, United Therapeutics has shown a remarkable growth trajectory, with its gross profit increasing by approximately 78%, peaking at $2.07 billion in 2023. In contrast, Perrigo's gross profit has experienced fluctuations, with a notable peak in 2016 at $2.05 billion, followed by a decline and subsequent recovery to $1.68 billion in 2023.

Key Insights

  • United Therapeutics: Demonstrated consistent growth, particularly from 2021 to 2023, with a 32% increase.
  • Perrigo: Despite a peak in 2016, the company faced a downturn, recovering slightly by 2023.

These trends highlight the dynamic nature of the pharmaceutical sector, where strategic decisions and market conditions significantly impact financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025